UNION therapeutics Announces Successful Phase 1 Study Completion with ATx201
COPENHAGEN, OCTOBER 22, 2018 – UNION, a privately held, clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders, today announced positive results from a Phase 1 Sensitization Study in 240 […]
AntibioTx Announces Company Name Change to UNION therapeutics
COPENHAGEN, OCTOBER 09, 2018 – Dr. Rasmus Toft-Kehler, Chief Executive Officer of AntibioTx, announced this week in Copenhagen that the company has officially changed its name to UNION therapeutics as […]
AntibioTx Expands Management Team with Dr. Umar Hayat
COPENHAGEN, JULY 01 2018 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the company has expanded the management team with Umar Hayat, […]
AntibioTx Announces Positive Data Supporting the Safety of ATx201
COPENHAGEN, JUNE 25, 2018 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders, has with the addition of two preclinical studies (Ocular Irritation and Phototoxicity) further strengthened ATx201’s safety […]
AntibioTx Strengthens Management Team with CFO and VP of Commercialization
COPENHAGEN, APRIL 02, 2018 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the company has expanded the management team with Morten Boesen as […]
FDA Approves IND to Conduct Clinical Studies with ATx201 in USA
COPENHAGEN, NOVEMBER 01 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the U.S Food and Drug Administration (FDA) has granted an Investigational […]
AntibioTx Signs 150 M DKK Financing Agreement with the European Investment Bank
COPENHAGEN, OCTOBER 26, 2017 – AntibioTx A/S has signed a 150 M DKK (20 M EUR) financing agreement with the European Investment Bank to support late-stage clinical trials for the […]
AntibioTx to Present Phase I DECOLAD Results at the 26th EADV
COPENHAGEN, JUNE 02, 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders has been invited to present Phase I DECOLAD results at the Annual Congress of […]
AntibioTx Announces New Board Members
COPENHAGEN, MAY 22, 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced three new board members. Joining AntibioTx board of directors are Stig Loekke […]
AntibioTx Announces Phase I Study Results for ATx201
COPENHAGEN, APRIL 05, 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders, today declared successful completion of a Phase I study with ATx201. The Study set out […]
